Avenue Therapeutics, Inc. (ATXI) P/E Ratio History
Historical price-to-earnings valuation from 2025 to 2025
Loading P/E history...
ATXI Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Avenue Therapeutics, Inc. (ATXI) trades at a price-to-earnings ratio of -0.6x, with a stock price of $0.55 and trailing twelve-month earnings per share of $-1.18.
The current P/E is 506% below its 5-year average of 0.2x. Over the past five years, ATXI's P/E has ranged from a low of 0.1x to a high of 0.2x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, ATXI trades at a 103% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, ATXI trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ATXI DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ATXI P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $930M | 147.8 | - | +107% | |
| $1B | 22.7 | 1.27 | -7% | |
| $1B | 177.5 | - | -79% | |
| $2B | 6.9Lowest | 0.67Best | +817%Best | |
| $92B | 29.2 | 0.75 | +15% | |
| $44B | 28.7 | - | +87% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
ATXI Historical P/E Data (2025–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | $0.79 | $3.82 | 0.2x | +37% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $0.20 | $2.11 | 0.1x | -37% |
Average P/E for displayed period: 0.2x
See ATXI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ATXI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ATXI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonATXI — Frequently Asked Questions
Quick answers to the most common questions about buying ATXI stock.
Is ATXI stock overvalued or undervalued?
ATXI trades at -0.6x P/E, below its 5-year average of 0.2x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does ATXI's valuation compare to peers?
Avenue Therapeutics, Inc. P/E of -0.6x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is ATXI's PEG ratio?
ATXI PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2025-2025.